⌕
Neurocrine Biosciences · NBIX · Nasdaq
Tenet 65 · Solid
Compare
$165.31−1.25%At closeTenet 65 · Solid
$165.31−2.09 (−1.25%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Neurocrine Biosciences (NBIX) Institutional Ownership

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice

5 figures withheld by our checks. Each blank figure names its reason.

13F fund flowQuarter ended Jun 30, 2026. Withheld: many filers have already reported a later quarter, so their changes in this quarter are not on file and the counts of new, added, trimmed and closed positions are not shown. These positions are 140 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 787 filers, Jun 30, 2026
# 13F FUNDS
787
13F VALUE
$17.2B
101.8M shares
Withheld: the 13F filers report more shares than the company has outstanding, which happens when shared or lent shares are counted twice. The filer count, shares and value are as filed.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Nov 4, 2026ROBERTS EIRYChief Medical OfficerAcquired · Grant / award8,314Stock Option—↗
Nov 4, 2026ROBERTS EIRYChief Medical OfficerAcquired · Grant / award1,506Restricted Stock Unit—↗
Nov 3, 2026MORROW GEORGE JdirectorAcquired · Option exercise7,200$53.64↗
Nov 3, 2026MORROW GEORGE JdirectorDisposed · Open-market sale100$158.18↗
Nov 3, 2026MORROW GEORGE JdirectorDisposed · Open-market sale100$162.05↗
Nov 3, 2026MORROW GEORGE JdirectorDisposed · Open-market sale600$163.71↗
Nov 3, 2026MORROW GEORGE JdirectorDisposed · Open-market sale1,226$164.74↗
Nov 3, 2026MORROW GEORGE JdirectorDisposed · Open-market sale908$165.71↗
Nov 3, 2026MORROW GEORGE JdirectorDisposed · Open-market sale1,466$166.77↗
Nov 3, 2026MORROW GEORGE JdirectorDisposed · Open-market sale1,500$167.72↗
Nov 3, 2026MORROW GEORGE JdirectorDisposed · Open-market sale1,300$168.53↗
Nov 3, 2026MORROW GEORGE JdirectorDisposed · Option exercise7,200Non-Qualified Stock Option—↗
Nov 2, 2026MORROW GEORGE JdirectorAcquired · Option exercise7,500$53.64↗
Nov 2, 2026MORROW GEORGE JdirectorDisposed · Open-market sale1,900$144.98↗
Nov 2, 2026MORROW GEORGE JdirectorDisposed · Open-market sale4,300$145.86↗
Nov 2, 2026MORROW GEORGE JdirectorDisposed · Open-market sale1,300$146.76↗
Nov 2, 2026MORROW GEORGE JdirectorDisposed · Option exercise7,500Non-Qualified Stock Option—↗
Nov 1, 2026Gano KyleChief Executive OfficerAcquired · Option exercise614—↗
Nov 1, 2026Gano KyleChief Executive OfficerDisposed · Tax withholding332$146.10↗
Nov 1, 2026Gano KyleChief Executive OfficerDisposed · Option exercise614Restricted Stock Unit—↗

* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How many 13F filers hold Neurocrine Biosciences?

Neurocrine Biosciences was held by 787 13F filers as of Jun 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.